$SYRA
Syra Health Corp Stock $syra

$syra Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224042875 Filed on October 29, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$2.253M	$1.581M
YoY Change		42.49%	4.45%
Cost Of Revenue		$1.585M	$1.027M
YoY Change		54.37%	-6.67%
Gross Profit		$668.3K	$554.5K
YoY Change		20.51%	34.01%
Gross Profit Margin		29.66%	35.07%
Selling, General & Admin		$288.3K	$234.1K
YoY Change		23.16%	55.55%
% of Gross Profit		43.14%	42.21%
Research & Development		$34.82K
YoY Change
% of Gross Profit		5.21%
Depreciation & Amortization		$25.54K	$12.36K
YoY Change		106.69%	218.48%
% of Gross Profit		3.82%	2.23%
Operating Expenses		$1.097M	$897.6K
YoY Change		22.24%	18.01%
Operating Profit		-$428.9K	-$343.0K
YoY Change		25.04%	-1.09%
Interest Expense		$11.37K	$14.18K
YoY Change		-19.82%	82.29%
% of Operating Profit
Other Income/Expense, Net		$11.38K	-$11.36K
YoY Change		-200.13%	46.69%
Pretax Income		-$417.5K	-$354.4K
YoY Change		17.82%
Income Tax
% Of Pretax Income
Net Earnings		-$417.5K	-$354.4K
YoY Change		17.82%	-0.04%
Net Earnings / Revenue		-18.53%	-22.41%
Basic Earnings Per Share		-$0.06	-$0.08
Diluted Earnings Per Share		-$0.06	-$0.08
COMMON SHARES
Basic Shares Outstanding	8.974M shares	6.612M shares	4.360M shares
Diluted Shares Outstanding		7.265M shares	4.360M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.697M	$18.01K
YoY Change	14877.57%
Cash & Equivalents	$2.697M	$18.01K
Short-Term Investments
Other Short-Term Assets	$483.0K	$163.3K
YoY Change	195.73%
Inventory
Prepaid Expenses	$409.9K
Receivables	$884.5K	$1.055M
Other Receivables	$483.0K	$163.3K
Total Short-Term Assets	$4.065M	$1.236M
YoY Change	228.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.63K	$91.33K
YoY Change	-62.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.185M
YoY Change
Total Long-Term Assets	$360.1K	$1.371M
YoY Change	-73.73%
TOTAL ASSETS
Total Short-Term Assets	$4.065M	$1.236M
Total Long-Term Assets	$360.1K	$1.371M
Total Assets	$4.425M	$2.607M
YoY Change	69.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$212.9K	$954.2K
YoY Change	-77.68%
Accrued Expenses	$309.6K	$274.6K
YoY Change	12.75%
Deferred Revenue
YoY Change
Short-Term Debt	$240.2K	$916.6K
YoY Change	-73.79%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$877.8K	$2.381M
YoY Change	-63.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.455M
YoY Change	-100.0%
Other Long-Term Liabilities	$216.6K	$0.00
YoY Change
Total Long-Term Liabilities	$216.6K	$1.455M
YoY Change	-85.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$877.8K	$2.381M
Total Long-Term Liabilities	$216.6K	$1.455M
Total Liabilities	$1.094M	$3.836M
YoY Change	-71.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.320M	-$4.070M
YoY Change	104.43%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.331M	-$1.229M
YoY Change
Total Liabilities & Shareholders Equity	$4.425M	$2.607M
YoY Change	69.75%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$417.5K	-$354.4K
YoY Change	17.82%	-0.04%
Depreciation, Depletion And Amortization	$25.54K	$12.36K
YoY Change	106.69%	218.48%
Cash From Operating Activities	-$413.3K	-$372.0K
YoY Change	11.09%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$4.750K
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$4.750K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.516M	351.9K
YoY Change	330.87%
NET CHANGE
Cash From Operating Activities	-413.3K	-372.0K
Cash From Investing Activities	0.000	4.750K
Cash From Financing Activities	1.516M	351.9K
Net Change In Cash	1.103M	-15.34K
YoY Change	-7291.07%
FREE CASH FLOW
Cash From Operating Activities	-$413.3K	-$372.0K
Capital Expenditures	$0.00	-$4.750K
Free Cash Flow	-$413.3K	-$367.3K
YoY Change	12.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	590263	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	288305	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	234084	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	369889	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	44398	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	325491	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001922335
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8973774	shares
CY2024Q3	us-gaap	Cash Cash	2697459	usd
CY2023Q4	us-gaap	Cash Cash	3280075	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	482990	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	389787	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	4064894	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34625	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78974	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	325491	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63199	usd
CY2024Q3	us-gaap	Assets Assets	4425010	usd
CY2023Q4	us-gaap	Assets Assets	4923283	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	212931	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	462991	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	309606	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6108	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108939	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63199	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	240221	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	184904	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	877805	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	910072	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1390256	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	SYRA HEALTH CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-4027995
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1119 Keystone Way N. #201
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
	dei	City Area Code CityAreaCode	(463)
	dei	Local Phone Number LocalPhoneNumber	345-8950
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not applicable
	dei	Security12b Title Security12bTitle	Class A Common Stock, $0.001 par value
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
	dei	Trading Symbol TradingSymbol	SYRA
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4781110	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	216552	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1094357	usd
CY2023Q4	us-gaap	Liabilities Liabilities	910072	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	SYRA	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2023Q4	SYRA	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5975357	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3748943	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4777765	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2919087	usd
	us-gaap	Gross Profit GrossProfit	1197592	usd
	us-gaap	Gross Profit GrossProfit	829856	usd
	us-gaap	Salaries And Wages SalariesAndWages	2178105	usd
	us-gaap	Salaries And Wages SalariesAndWages	1612605	usd
	us-gaap	Professional Fees ProfessionalFees	424379	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1147142	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	657904	usd
	us-gaap	Depreciation Depreciation	55460	usd
	us-gaap	Depreciation Depreciation	36413	usd
	us-gaap	Operating Expenses OperatingExpenses	4460809	usd
	us-gaap	Operating Expenses OperatingExpenses	2731301	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3263217	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1901445	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	18448	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2826	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10072	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	44449	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8376	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41623	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3254841	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1943068	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties		usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	SYRA	Initial Recognition Of Rightofuse Asset And Lease Liability InitialRecognitionOfRightofuseAssetAndLeaseLiability		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
CY2024Q3	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity File Number EntityFileNumber	001-41822
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	198978	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11640642	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9071745	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8319796	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5064955	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	3330653	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4013211	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4425010	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4923283	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2253336	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1581344	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1585038	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1026803	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	668298	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	554541	usd
CY2024Q3	us-gaap	Salaries And Wages SalariesAndWages	594738	usd
CY2023Q3	us-gaap	Salaries And Wages SalariesAndWages	592241	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	153803	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	58875	usd
	us-gaap	Professional Fees ProfessionalFees	489839	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34821	usd
CY2024Q3	us-gaap	Depreciation Depreciation	25541	usd
CY2023Q3	us-gaap	Depreciation Depreciation	12357	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1097208	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	897557	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-428910	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-343016	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	13641	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2820	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2266	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	14180	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11375	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11360	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-417535	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-354376	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7264768	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7264768	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4360426	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4360426	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6789209	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6789209	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4380267	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4380267	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4013211	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18875	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	850129	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14140	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1447050	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3449305	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18875	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14346	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2092270	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1619021	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22874	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14023	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-417535	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	3330653	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	710098	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1367	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-785892	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-74427	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1223	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-802800	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-876004	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-876004	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1079	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-354376	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1229301	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1229301	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3254841	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1943068	usd
	us-gaap	Depreciation Depreciation	55460	usd
	us-gaap	Depreciation Depreciation	36413	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9922	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	74647	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	63199	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	90162	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	28486	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3669	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-176189	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-136324	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-50614	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-285456	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-58979	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-250060	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	500391	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	18221	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6108	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	141644	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	110628	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	35479	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-63199	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-90162	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2717313	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1002026	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11111	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15251	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11111	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15251	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2469150	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	589059	usd
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	300000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	750397	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1295010	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	678611	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	323342	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1455000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2145808	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1031943	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-582616	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14666	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3280075	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2697459	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18010	usd
	us-gaap	Interest Paid Net InterestPaidNet	10072	usd
	us-gaap	Interest Paid Net InterestPaidNet	28533	usd
	SYRA	Initial Recognition Of Rightofuse Asset And Lease Liability InitialRecognitionOfRightofuseAssetAndLeaseLiability	325491	usd
	us-gaap	Notes Issued1 NotesIssued1	378659	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zM5Nd5anf0q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_znMo1a4KmiS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concentrations of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_c20240930_zK8WeLVZ0qT7" title="FDIC insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at September 30, 2024. The Company has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	5520	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5520	usd
	us-gaap	Revenues Revenues	5975357	usd
	us-gaap	Revenues Revenues	3748943	usd
CY2024Q3	us-gaap	Cash Cash	2697459	usd
CY2024Q3	SYRA	Working Capital WorkingCapital	3187089	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8319796	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1455000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5332283	usd
CY2024Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1619021	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8346217	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28000	shares
CY2024Q3	us-gaap	Prepaid Taxes PrepaidTaxes	73069	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	73069	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	409921	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	316718	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	482990	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	389787	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	119287	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63826	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34625	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78974	usd
	us-gaap	Depreciation Depreciation	55460	usd
	us-gaap	Depreciation Depreciation	36413	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	264339	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	148924	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	45267	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50054	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	309606	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	198978	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04	pure
	SYRA	Investment Retirement Account Contribution Expenses InvestmentRetirementAccountContributionExpenses	79493	usd
	SYRA	Investment Retirement Account Contribution Expenses InvestmentRetirementAccountContributionExpenses	66590	usd
CY2024Q3	SYRA	Accrued Retirement Contributions AccruedRetirementContributions	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	96825	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	90162	usd
	SYRA	Operating Lease Interest Expense OperatingLeaseInterestExpense	1065	usd
	SYRA	Operating Lease Interest Expense OperatingLeaseInterestExpense	6233	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	97890	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	96395	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	325491	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63199	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108939	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63199	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	216552	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	325491	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	63199	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0925	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	134505	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	134505	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	100879	usd
CY2024Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y9M
CY2024Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2050000.00	usd
CY2024Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1619021	usd
CY2024Q3	us-gaap	Share Price SharePrice	0.80
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	50000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56625	usd
	us-gaap	Other Expenses OtherExpenses	10753	usd
	SYRA	Number Of Options Vested NumberOfOptionsVested	0.25	pure
CY2024Q3	SYRA	Number Of Options Vested NumberOfOptionsVested	0.25	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	55116	usd
CY2024Q3	us-gaap	Unamortized Discounts On Acceptances Executed UnamortizedDiscountsOnAcceptancesExecuted	171555	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	140750	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	42000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.65
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	32500	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	150250	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y7M24D

Files In Submission

Name	View Source	Status
0001493152-24-042875-index-headers.html	Edgar Link	pending
0001493152-24-042875-index.html	Edgar Link	pending
0001493152-24-042875.txt	Edgar Link	pending
0001493152-24-042875-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syra-20240930.xsd	Edgar Link	pending
syra-20240930_cal.xml	Edgar Link	unprocessable
syra-20240930_def.xml	Edgar Link	unprocessable
syra-20240930_lab.xml	Edgar Link	unprocessable
syra-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SYRA
Syra Health Corp Stock $syra

2024 Q4 Form 10-Q Financial Statement

#000149315224042875 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SYRA Syra Health Corp Stock $syra

2024 Q4 Form 10-Q Financial Statement

#000149315224042875 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SYRA
Syra Health Corp Stock $syra